¶ resolution
¶ Definition
The active, coordinated biological program that terminates inflammation and restores tissue Homeostasis. Resolution is not passive decay but an ATP-requiring process orchestrated by Specialized pro-resolving mediators (SPMs) that actively stops neutrophil recruitment, promotes Efferocytosis, reprograms macrophages to anti-inflammatory phenotypes, and initiates wound healing. Failed resolution—not excessive inflammatory initiation—is the root cause of chronic inflammation.
¶ Picture It
Think of inflammation as a fire department responding to a house fire. The initial response brings trucks, hoses, and firefighters (neutrophils, cytokines, Prostaglandins)—necessary to put out the flames. But here's the critical part: resolution is not just "the fire going out by itself." It's the active cleanup crew that arrives in specialized vehicles equipped with different tools.
This cleanup crew (Resolvins, Maresins, Protectins) does four essential jobs: (1) they radio dispatch to stop sending more fire trucks (neutrophil recruitment cessation), (2) they sweep up debris and neutralize smoke damage (Efferocytosis of dead cells), (3) they convert the remaining firefighters into building inspectors who assess structural damage rather than spray more water (M2 macrophages polarization), and (4) they actively begin rebuilding the structure (wound healing, tissue repair).
Without this active cleanup crew, you'd have fire trucks parked indefinitely, debris accumulating, and continuous smoke damage—this is chronic inflammation. The house never gets rebuilt; it just stays in a perpetual state of emergency response. Worse, if you block the cleanup crew with NSAIDs (which also block COX-2 needed to make SPMs) or chronic ice application, you prevent the very mechanism that shuts down inflammation properly.
¶ Mechanism
Resolution is initiated by a coordinated lipid mediator class switch from pro-inflammatory to pro-resolving molecules:
Class Switch Cascade:
Arachidonic acid → COX-2 → PGE2/Prostaglandins (pro-inflammatory, peak 6-12h)
↓
Lipid mediator class switching triggered by:
- Declining neutrophil influx
- Rising Efferocytosis signals
- Cellular redox changes
- Transcriptional reprogramming (NF-κB suppression)
↓
Omega-3 fatty acids (EPA/DHA) → 15-LOX/5-LOX/12-LOX → Specialized pro-resolving mediators (SPMs):
- Resolvins (RvD1-6, RvE1-3)
- Maresins (MaR1, MaR2)
- Protectins (PD1/NPD1)
- Lipoxins (LXA4, aspirin-triggered 15-epi-LXA4)
SPM Receptor Signaling:
Cellular Resolution Program:
-
Neutrophil phase termination (Resolution Interval Ri = time from peak inflammation to 50% neutrophil clearance):
- SPMs block CXCL1/CXCL2 chemokine gradients
- Neutrophils undergo apoptosis (not necrosis)
- Surface expression of "eat me" signals (phosphatidylserine externalization)
-
Efferocytosis enhancement:
- RvD1/MaR1 upregulate phagocytic receptors on macrophages
- CD36, integrin αvβ3, MerTK receptor expression ↑
- Non-inflammatory engulfment (no TNF-α/IL-1β release)
- Each macrophage can clear 20+ apoptotic neutrophils
-
Macrophage reprogramming:
- M1 macrophages (iNOS+, TNF+) → M2 macrophages (Arg1+, IL-10+, CD206+)
- RvD2 → ALX-FPR2 → ↑ IL-10, ↓ IL-12
- Metabolic shift: glycolysis → oxidative phosphorylation
- Secretion of pro-repair factors: TGF-beta, VEGF, Amphiregulin
-
Pain resolution:
- SPMs bind TRPV1/TRPA1 on sensory neurons
- Reduce Substance P and CGRP release
- Block TNF-α-induced hyperalgesia
- Analgesic effect independent of anti-inflammatory action
-
Tissue regeneration initiation:
- Stimulate fibroblasts → Collagen I/Collagen III synthesis
- Promote angiogenesis (VEGF signaling)
- Activate satellite cells in muscle
- Prevent excessive fibrosis (balanced ECM remodeling)
Quantitative Resolution Indices:
- Ri (Resolution Interval): Time from peak PMN infiltration to 50% reduction (healthy: <24h)
- Ψmax: Maximum neutrophil count at inflammation peak
- T50: Time to 50% neutrophil reduction
- Tmax: Time to peak inflammation
¶ Clinical Significance
Paradigm Shift in Clinical Practice:
The resolution framework fundamentally reframes chronic disease treatment. Instead of viewing inflammation as "the enemy" requiring suppression, cPNI recognizes that failed resolution is the actual pathology. This explains why:
- Anti-inflammatory drugs often worsen outcomes long-term: NSAIDs block COX-2, preventing both Prostaglandins and aspirin-triggered Resolvins. Chronic NSAID use prolongs wound healing by 30-50% and increases chronic pain risk.
- Chronic ice application impairs healing: Ice blocks the COX-2-mediated class switch to SPMs. Use acute ice (<48h) only, never chronically.
- Omega-3 supplementation has pleiotropic benefits: Not because omega-3s "reduce inflammation" but because they provide substrate for SPM synthesis. Target omega-3 index >8% for optimal resolution capacity.
Metamodel Connections:
This concept is central to understanding why chronic diseases cluster (Metamodel 5 plus 2): chronic activation of survival systems (inflammation, cortisol, sympathetic nervous system) without reaching resolution creates perpetual emergency metabolism.
Clinical Conditions with Failed Resolution:
-
Chronic inflammatory diseases:
- Rheumatoid arthritis: Synovial fluid shows low RvD1, high LTB4/PGE2 ratio
- IBD: Colonic mucosa depleted in Lipoxins, excess Leukotriene B4
- Atherosclerosis: Plaques accumulate uncleared apoptotic cells (efferocytosis failure)
- Chronic pain syndromes: Persistent neuroinflammation without SPM-mediated analgesia
-
Metabolic dysfunction:
- Obesity: Adipose tissue shows chronic macrophage infiltration (M1 > M2)
- Type 2 Diabetes: Pancreatic islets fail to resolve inflammation → beta-cell death
- NAFLD: Hepatic stellate cells activated chronically → fibrosis
-
Neurodegenerative disease:
- Alzheimer's Disease: Brain shows low NPD1, impaired microglial Efferocytosis
- Parkinson's Disease: Substantia nigra inflammation persists without resolution
Intervention Strategy:
Support resolution, don't just block inflammation:
-
Substrate provision:
-
Remove resolution blockers:
- Discontinue chronic NSAID use (acute use
-5 days acceptable) - Replace with resolution-promoting interventions: Curcumin (↑ 15-LOX), Resveratrol (↑ SPM receptors)
- Avoid chronic ice; use after acute phase only
- Discontinue chronic NSAID use (acute use
-
Enhance efferocytosis:
- Address hyperglycaemia (AGEs impair "eat me" signal recognition)
- Optimize Vitamin D (calcitriol enhances CD36 expression on macrophages)
- Ensure adequate Zinc (required for membrane remodeling during phagocytosis)
-
Time interventions appropriately:
- Early phase (0-24h): Allow pro-inflammatory response (necessary for pathogen clearance)
- Transition phase (24-72h): Support class switch with omega-3s, avoid NSAID
- Resolution phase (72h+): Enhance efferocytosis, M2 polarization, tissue repair
-
Address upstream causes:
- Chronic psychological stress → sustained cortisol → Glucocorticoid Receptor resistance → impaired SPM signaling
- Leaky gut → chronic endotoxemia → continuous re-ignition of inflammation
- Hypothalamic Inflammation → dysregulated inflammatory set-points
Biomarker Assessment:
- Plasma SPM profiling (RvD1, RvE1, MaR1 levels)—emerging clinical test
- Omega-3 index (erythrocyte EPA+DHA %)—widely available
- Inflammatory:resolving lipid ratios (LTB4:RvE1, PGE2:LXA4)
- CRP/IL-6 trajectory over time (should decline post-acute phase)
- neutrophil-to-lymphocyte ratio (elevated in failed resolution)
¶ Key Facts
- Resolution is an active, ATP-requiring process, not passive inflammatory decay—requires 15-LOX, 5-LOX enzymes actively synthesizing SPMs
- Lipid mediator class switching occurs 12-24h post-inflammatory peak: arachidonic acid pathways shift from COX-2→PGE2 to LOX→SPMs
- Resolution Interval (Ri) in healthy tissue: <24h; chronic inflammation shows Ri >72h or no measurable Ri
- Aspirin uniquely supports resolution by acetylating COX-2 → production of aspirin-triggered resolvins (15-epi-LXA4, AT-RvD1) at low doses (75-100mg/day)
- Each RvD1 molecule can stop recruitment of ~40,000 neutrophils and enhance macrophage efferocytosis of 10-20 apoptotic cells
- NSAIDs block resolution by inhibiting COX-2, preventing both prostaglandin and resolvin synthesis—prolongs wound healing by 30-50%
- Omega-3 index >8% correlates with higher SPM production capacity; <4% associated with impaired resolution in multiple tissues
- Chronic obesity shows 10-100x higher LTB4:RvD1 ratio in adipose tissue compared to lean controls
- M2 macrophages phenotype transition requires 48-72h after initial M1 response—premature suppression blocks effective pathogen clearance
- RvE1 is 10,000x more potent than aspirin in reducing PMN infiltration in inflammation models (nanomolar vs. millimolar concentrations)
- Failed efferocytosis (uncleared apoptotic cells) triggers secondary necrosis → DAMPs release → re-ignition of inflammation (chronic loop)
- Chronic ice application (>72h) reduces SPM synthesis by 60-80% in injured tissue—acute ice (<24h) is acceptable for pain/swelling control
¶ Connections
- Specialized pro-resolving mediators (SPMs) — molecular effectors driving active resolution through receptor-mediated signaling
- inflammation — resolution is the essential terminal phase; without it, acute inflammation becomes chronic disease
- Efferocytosis — clearance of apoptotic neutrophils by macrophages; SPMs enhance phagocytic receptor expression (CD36, MerTK)
- Lipid mediator class switching — metabolic shift from pro-inflammatory (PGE2, LTB4) to pro-resolving (Resolvins, Maresins) lipid mediators
- M2 macrophages — resolution phenotype; SPMs drive M1→M2 polarization through PPARγ and IL-10 signaling
- neutrophils — resolution begins when neutrophil recruitment ceases and apoptosis is initiated; SPMs block CXCL chemokine gradients
- chronic inflammation — results from failed resolution mechanisms rather than excessive inflammatory initiation
- wound healing — resolution phase overlaps with proliferative phase; SPMs stimulate fibroblast collagen synthesis and angiogenesis
- tissue repair — resolution actively promotes regeneration through VEGF, TGF-β, and Amphiregulin secretion from M2 macrophages
- Omega-3 fatty acids — EPA and DHA are essential substrates for resolvin, maresins, and protectin synthesis via 15-LOX/5-LOX pathways
- NSAIDs — block COX-2, preventing both prostaglandin and aspirin-triggered resolvin production; impair resolution when used chronically
- COX-2 — required enzyme for both inflammatory (PGE2) and resolution (aspirin-triggered resolvins) lipid mediators
- acute inflammation — physiological response requiring progression through resolution to prevent transition to chronic state
- Resoleomics — systems biology field mapping resolution pathways; quantifies SPM metabolomes and resolution indices (Ri, Ψmax, T50)
- cytokines — pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) actively suppressed during resolution via SOCS1/SOCS3 upregulation
- fibrosis — prevented by successful resolution; failed resolution leads to TGF-β-driven excessive collagen deposition
- pain — SPMs provide direct analgesia independent of anti-inflammatory effects through TRPV1/TRPA1 modulation on sensory neurons
- immunometabolism — resolution requires metabolic shift in macrophages from glycolysis (M1) to oxidative phosphorylation (M2)
- Lipoxins — first-discovered SPMs; LXA4 produced via 15-LOX from arachidonic acid; blocks neutrophil adhesion and transmigration
- Resolvins — D-series (from DHA) and E-series (from EPA); bind ALX-FPR2, ChemR23 receptors to terminate inflammation and enhance efferocytosis
- Maresins — macrophage mediators in resolving inflammation; MaR1 potently drives M2 polarization and phagocytosis
- Protectins — neuroprotective SPMs; NPD1/PD1 critical for brain inflammation resolution and synaptic integrity
- M1 macrophages — initial inflammatory phenotype; must transition to M2 for resolution; chronic M1 persistence defines failed resolution
- gut permeability — chronic barrier dysfunction → continuous LPS exposure → prevents resolution phase completion; treat barrier first
- cortisol — chronic elevation causes glucocorticoid receptor resistance → impaired SPM receptor signaling → resolution failure
- Hypothalamic Inflammation — prevents proper resolution signaling in neuroendocrine control centers; creates systemic resolution deficits
- Atherosclerosis — plaque progression driven by failed efferocytosis of apoptotic foam cells; resolvin administration shrinks plaques in models
- Rheumatoid arthritis — synovial fluid shows 100-fold elevation of LTB4:RvD1 ratio; joint damage correlates with resolution deficit
- Type 2 Diabetes — pancreatic inflammation persists without resolution → progressive beta-cell loss; RvD1 preserves islet function
- Alzheimer's Disease — microglial resolution failure leads to chronic neuroinflammation and plaque accumulation; NPD1 is neuroprotective
- Obesity — adipose tissue macrophages stuck in M1 state; failed resolution drives insulin resistance and metabolic dysfunction
- Chronic pain syndromes — spinal cord neuroinflammation without SPM-mediated resolution; intrathecal RvE1 reduces neuropathic pain in models
¶ Module References
- Module 1: Introduction to Clinical PNI — resolution framework as paradigm shift from symptom suppression to root cause treatment
- Module 5: Organs Module — resolution mechanisms in tissue-specific inflammation and repair processes across organ systems